UNICA IRIS Institutional Research Information System

PERSANO, MARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 18.998
NA - Nord America 1.220
AS - Asia 908
SA - Sud America 135
AF - Africa 20
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 21.286
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 18.553
US - Stati Uniti d'America 1.170
SG - Singapore 361
CN - Cina 312
SE - Svezia 137
BR - Brasile 107
DE - Germania 77
VN - Vietnam 56
FR - Francia 46
GB - Regno Unito 42
IN - India 42
HK - Hong Kong 34
FI - Finlandia 32
CA - Canada 30
NL - Olanda 28
KR - Corea 22
AT - Austria 18
PL - Polonia 18
MX - Messico 12
ES - Italia 11
JP - Giappone 11
AR - Argentina 9
BD - Bangladesh 8
IE - Irlanda 8
IQ - Iraq 7
AE - Emirati Arabi Uniti 6
BE - Belgio 6
EC - Ecuador 6
IR - Iran 6
PK - Pakistan 6
VE - Venezuela 6
MA - Marocco 5
TH - Thailandia 5
TR - Turchia 5
AU - Australia 4
PH - Filippine 4
UZ - Uzbekistan 4
ZA - Sudafrica 4
CH - Svizzera 3
GR - Grecia 3
ID - Indonesia 3
IL - Israele 3
PY - Paraguay 3
RU - Federazione Russa 3
AM - Armenia 2
DM - Dominica 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
JO - Giordania 2
NG - Nigeria 2
PE - Perù 2
PT - Portogallo 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
AL - Albania 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HR - Croazia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LT - Lituania 1
LU - Lussemburgo 1
MN - Mongolia 1
MO - Macao, regione amministrativa speciale della Cina 1
MY - Malesia 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
UA - Ucraina 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 21.286
Salva come PNG Salva come JPEG
Città #
Cagliari 17.432
Uta 989
Ashburn 195
Singapore 185
Dallas 124
Boardman 98
Nyköping 77
Beijing 66
Los Angeles 59
Chandler 55
Fairfield 51
Hefei 44
New York 32
Hong Kong 31
Santa Clara 30
Chicago 28
Rome 26
Seattle 26
Houston 25
Seoul 22
Munich 21
Helsinki 20
Ho Chi Minh City 20
Pune 19
Shanghai 19
Woodbridge 18
Boston 17
Cambridge 17
The Dalles 17
Amsterdam 16
Buffalo 15
Guangzhou 15
San Diego 15
São Paulo 15
Wilmington 15
Nuremberg 14
Redondo Beach 13
Warsaw 13
Hanoi 12
Montreal 11
Stockholm 11
Salt Lake City 10
Shenzhen 10
Düsseldorf 9
Frankfurt am Main 9
Lappeenranta 9
London 9
Toronto 9
Roubaix 8
Vienna 8
Zhengzhou 7
Dublin 6
Paris 6
Rio de Janeiro 6
Brooklyn 5
Chennai 5
Council Bluffs 5
Dubai 5
Florence 5
Menlo Park 5
Milan 5
Tianjin 5
Tokyo 5
Baghdad 4
Belo Horizonte 4
Bexley 4
Brussels 4
Dong Ket 4
La Maddalena 4
Manila 4
Mexico City 4
Naples 4
Poplar 4
Romainville 4
Tashkent 4
Wuhan 4
Atlanta 3
Casablanca 3
Clifton 3
Elk Grove Village 3
Haiphong 3
Jacksonville 3
Johannesburg 3
Las Vegas 3
Nakano 3
Nanjing 3
Orem 3
Peristeri 3
Porto Alegre 3
Portsmouth 3
Quito 3
San Cipriano d'Aversa 3
San Francisco 3
Sassari 3
Sydney 3
São Bernardo do Campo 3
Turin 3
Turku 3
Vancouver 3
Zurich 3
Totale 20.203
Salva come PNG Salva come JPEG
Nome #
Molecular-biology-driven treatment for metastatic colorectal cancer 2.718
New therapeutic targets in pancreatic cancer 1.593
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.491
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.308
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.184
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.006
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 946
Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab 910
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 904
Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast? 901
The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment 816
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 744
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 715
Uncovering key targets of success for immunotherapy in pancreatic cancer 680
Retrospective survival analysis in patients with metastatic pancreatic ductal adenocarcinoma with insulin-treated type 2 diabetes mellitus 624
BRCA-mutant pancreatic ductal adenocarcinoma 584
Immune Checkpoint Inhibitors in the Treatment of HCC 552
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 530
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment 514
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 335
Validation of the easy-to-use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib 327
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 264
Identification of Atezolizumab Plus Bevacizumab Prognostic Index via Recursive Partitioning Analysis in HCC: The ABE Index 235
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 228
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 222
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 175
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 168
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 157
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 156
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients 154
Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience 148
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy 57
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 35
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 26
Totale 21.407
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.480
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.480
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021969 0 0 0 0 0 283 94 163 63 161 109 96
2021/20221.411 84 65 4 47 57 107 68 164 112 154 244 305
2022/20233.457 301 460 353 253 266 336 167 257 238 379 291 156
2023/20243.389 144 130 116 191 285 576 596 252 191 206 335 367
2024/20259.142 2.411 2.892 824 954 437 609 481 53 103 161 84 133
2025/20261.459 265 192 251 282 243 226 0 0 0 0 0 0
Totale 21.407